PTC Therapeutics, Inc. (PTCT)
| Previous close | 33.10 |
| Open | 38.50 |
| Bid | 39.71 x 100 |
| Ask | 48.60 x 200 |
| Day's range | 37.57 - 40.24 |
| 52-week range | 17.53 - 59.84 |
| Volume | |
| Avg. volume | 866,974 |
| Market cap | 3.06B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.69 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 28.27 |
Investor's Business DailyPTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day'
PTC stock opened at a nine-month high Monday after the EC decided against pulling its drug, Translarna, from the market.
PR NewswirePTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has decided not to adopt the CHMP's negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna™ (ataluren) and has returned the opinion to the CHMP for re-evaluation. As a result, Translarna remains on the market and available for patients in Europe consistent with its current marketing authorization. The EC has asked the CHMP to further consider the to
PR NewswirePTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024.
